PLEASANTON, Calif., Aug. 6 Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it will be participating in the Canaccord Adams 29th Annual Global Growth Conference on Thursday, August 13.
Advertisement
Gary F. Burbach, president and chief executive officer, will provide an update on the company, beginning at 10:30 a.m., Eastern Daylight Time (7:30 Pacific Daylight Time).
Advertisement
The presentation will be available through the conference website at http://www.wsw.com/webcast/canaccord/thor/ or on the company's website at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 13,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at http://www.thoratec.com or http://www.itcmed.com.
SOURCE Thoratec Corporation
